Citi has issued a research report following the joint release of the 15th Five-Year Plan for the Pharmaceutical Industry Development by the Ministry of Industry and Information Technology and other departments. The plan focuses on shifting China's pharmaceutical industry from scale-driven growth to innovation-led, quality-oriented development, with a clear objective of achieving world-leading status by 2030. The coverage spans innovative drugs, advanced medical devices, AI-powered drug discovery, and CDMO/CRO services, reflecting broad policy support across the entire value chain.

The bank believes this policy direction benefits domestic innovative drug developers and biotech firms, AI-driven drug discovery companies, CRO/CDMO service providers, high-end medical device manufacturers, in-vitro diagnostics (IVD) equipment producers, and innovative traditional Chinese medicine enterprises. Citi's top picks in this space include CSPC PHARMA (01093), HENGRUI PHARMA (01276), INNOVENT BIO (01801), SKB BIO (06990), WUXI BIO (02269), TIGERMED (03347), and 英硅智能 (03696).